Roche receives CE Mark for its Chest Pain Triage algorithm to enhance detection of Acute Coronary Syndrome (ACS)
By Dr. Matthew Watson
Basel, 23 April 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the introduction of its innovative Chest Pain Triage algorithm as part of the navify? Algorithm Suite. This groundbreaking algorithm is designed to more quickly and accurately detect Acute Coronary Syndrome (ACS) in patients presenting with chest pain, one of the most common reasons for Emergency Department (ED) visits. As EDs are typically one of the most crowded hospital units, leading to challenges to swiftly diagnose critical conditions, such as chest pain.4 This new algorithm was developed in collaboration with Universitätsklinikum Heidelberg.
See the article here:
Roche receives CE Mark for its Chest Pain Triage algorithm to enhance detection of Acute Coronary Syndrome (ACS)
Related Post
- Davos Alzheimer’s Collaborative Selects PacBio as Technology Partner for Global Project to Advance Alzheimer’s Disease Research in North Africa - April 23rd, 2025
- Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala - April 23rd, 2025
- Cambridge’s DIOSynVax and Singapore’s ACM Biolabs to Advance Pandemic-Ready Universal Bird Flu Vaccine with International Support - April 23rd, 2025
- NewGen Filed 2024 Annual Report on Form 20-F - April 23rd, 2025
- Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs - April 23rd, 2025
- Oncotelic CEO Vuong Trieu to Present Innovative "Deciparticles" Platform at IDDST-Europe 2025 Conference in Stockholm - April 23rd, 2025
- Elite Clinical Network and HealthyU Clinics Announce Strategic Partnership to Expand Access to Clinical Research - April 23rd, 2025
- Andrew Taylor joins Novonesis’ Executive Leadership Team - April 23rd, 2025
- Sirona Biochem Announces Debenture Financing - April 23rd, 2025
- Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors - April 23rd, 2025
- Digicann Ventures Provides Update Regarding Proposed RTO Transaction - April 23rd, 2025
- Pacira BioSciences to Present 104-Week Efficacy Data Following a Single Local Administration of PCRX-201 for Patients with Mild to Severe... - April 23rd, 2025
- Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones - April 23rd, 2025
- Longeveron® Issues Letter to Shareholders Highlighting Corporate Strategy, Recent Progress and Key Priorities and Goals for 2025 - April 23rd, 2025
- UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates - April 23rd, 2025
- NurExone Appoints Biotech Industry Leader - Jacob Licht to Lead U.S. Operations and Exo-Top Manufacturing Expansion and Completes Continuance into... - April 23rd, 2025
- OBI Pharma Announces Poster Presentations at the AACR 2025 Annual Meeting for OBI-992 and OBI-902 Antibody-Drug Conjugates (ADCs), GlycOBI® and... - April 23rd, 2025
- Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025 - April 23rd, 2025
- VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a... - April 23rd, 2025
- Preliminary Results for the Year Ended 31 December 2024 - April 14th, 2025
- Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects - April 14th, 2025
- Bioxytran Marks 50 years of Mitochondrial Research with BXT-25 Advancements - April 14th, 2025
- BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study - April 14th, 2025
- Scilex Holding Company Announces 1-for-35 Reverse Stock Split - April 14th, 2025
- Nika Pharmaceuticals, Inc. (NIKA) Latest Developments - April 14th, 2025
- TestoPrime Reviews: Best Testosterone Booster Supplement For Men Over 40 & 50 – Is TestoPrime Tablets Safe? - April 14th, 2025
- Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 14th, 2025
- Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and... - April 14th, 2025
- argenx Announces Annual General Meeting of Shareholders on May 27, 2025 - April 14th, 2025
- Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 14th, 2025
- Organogenesis Supports CMS’ Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High... - April 14th, 2025
- 4DMT Announces New Employment Inducement Grants - April 14th, 2025
- Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements - April 14th, 2025
- DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document - April 14th, 2025
- Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - April 14th, 2025
- Kane Biotech Announces New Agreement with Outside the Box Capital Inc. - April 14th, 2025
- Theratechnologies Responds to Future Pak’s Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the... - April 14th, 2025
- European Commission approves Roche’s Columvi as the first bispecific antibody for diffuse large B-cell lymphoma after initial therapy - April 14th, 2025
- Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US - April 14th, 2025
- Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates - March 31st, 2025
- HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results - March 31st, 2025
- Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - March 31st, 2025
- Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors - March 31st, 2025
- Enzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX - March 31st, 2025
- Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results - March 31st, 2025
- HilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company Progress - March 31st, 2025
- Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates - March 31st, 2025
- Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension... - March 31st, 2025
- Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery... - March 31st, 2025
- Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025 - March 31st, 2025
- Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress - March 31st, 2025
- Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study - March 31st, 2025
- First Three Children to Commence Treatment With Ryoncil® - March 31st, 2025
- BioVersys Announces Important BV100 Patent Granted by Chinese Patent Office - March 31st, 2025
- Opthea Announces Decision to Discontinue Wet AMD Trials - March 31st, 2025
- Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the... - March 31st, 2025
- Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA - March 31st, 2025
- AAVantgarde and TIGEM Publish Groundbreaking Research in Science Advances - March 31st, 2025
- NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025 - March 31st, 2025
- Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting - March 22nd, 2025
- FDA Approves New Prostate Cancer Imaging Agent Gozellix® - March 22nd, 2025
- OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category - March 22nd, 2025
- 23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and Accompanying Lab Test - March 22nd, 2025
- Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update - March 22nd, 2025
- Pharmaceutical industry delivers value proposition to Finnish Government: billions to be invested by 2030 - March 22nd, 2025
- BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025 - March 22nd, 2025
- PharmAla Completes Shipment of LaNeo™ MDMA to the University of Washington - March 22nd, 2025
- Bright Green Corporation Announces the next steps for the completion of its restructuring plan - March 22nd, 2025
- Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million - March 22nd, 2025
- Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones - March 22nd, 2025
- Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX - March 22nd, 2025
- Impact Biomedical Inc. Announcement Stock Activity/Pricing - March 22nd, 2025
- I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - March 22nd, 2025
- Better Choice Company Shareholders Overwhelmingly Approve Acquisition of SRx Health Solutions and Related Proposals - March 22nd, 2025
- Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results - March 22nd, 2025
- Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting... - March 22nd, 2025
- Atea Pharmaceuticals Issues Statement Regarding Director Nominations - March 22nd, 2025
- Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc. - March 22nd, 2025
- Arialief Reviews (Is It Safe And Legit To Use?) What Do Arialief Consumer Reports Say About Its Efficacy? - March 22nd, 2025
- Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of... - March 11th, 2025
Global News Feed
Comments Off on Roche receives CE Mark for its Chest Pain Triage algorithm to enhance detection of Acute Coronary Syndrome (ACS) |
April 23rd, 2025
This author published 6172 posts in this site.Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research